Litigation Details for Acerta Pharma B.V. v. Cipla Limited (D. Del. 2022)
✉ Email this page to a colleague
Acerta Pharma B.V. v. Cipla Limited (D. Del. 2022)
| Docket | ⤷ Start Trial | Date Filed | 2022-02-02 |
| Court | District Court, D. Delaware | Date Terminated | 2024-07-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Gregory B. Williams |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Parties | ASTRAZENECA AB | ||
| Patents | 10,167,291; 10,239,883; 10,272,083; 7,459,554; 9,758,524; 9,796,721 | ||
| Attorneys | Matthew B. Goeller | ||
| Firms | Heyman Enerio Gattuso & Hirzel LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Acerta Pharma B.V. v. Cipla Limited
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Acerta Pharma B.V. v. Cipla Limited (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-02-02 | External link to document | |||
| 2022-02-02 | 15 | Stipulation-General (See Motion List for Stipulation to Extend Time) | Dismissing Claims Regarding U.S. Patent Nos. 9,758,524; 10,239,883; and 10,272,083 Without Prejudice … 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-02-02 | 16 | Order | Proposed Order Claims Regarding U.S. Patent Nos. 9,758,524; 10,239,883; and 10,272,083 Without Prejudice.… 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-02-02 | 4 | Patent/Trademark Report to Commissioner of Patents | 10,239,883 ;9,796,721 ;10,167,291 ;10,272,083. (mal) (Entered: 02/02/2022) 2 February 2022 PACER… Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,758,524 ;10,… 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-02-02 | 60 | Stipulation-General (See Motion List for Stipulation to Extend Time) | Claims Against Cipla Regarding U.S. Patent Nos. 9,758,524 and 10,239,883 Without Prejudice by AstraZeneca… 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2022-02-02 | 89 | Stipulation-General (See Motion List for Stipulation to Extend Time) | Construction for U.S. Patent Nos. 9,758,524; 10,239,883; 9,796,721; 10,167,291; 10,272,083 by Acerta … 2 February 2022 1:22-cv-00154 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
